|
Powered by Cell Signaling Technology |
|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| RkDsEGysESPDLEF SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 25291658 |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Disease tissue studied: | |
| Relevant cell line - cell type - tissue: | |
| References | |
|---|---|
|
Borenäs M, et al. (2024) ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition. Proc Natl Acad Sci U S A 121, e2315242121
38154064 Curated Info |
|
|
Possemato A (2008) CST Curation Set: 5316; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info |
